XO1 is an asset-centric biotech company developing ichorcumab, an antibody against human thrombin exosite 1 that has the potential to deliver antithrombotic efficacy without increased propensity to bleed.
Thrombosis, the tendancy for blood to clot and block blood vessels inappropriately, is a major cause of morbidity and mortality, contributing to heart attacks, strokes, embolism and deep vein thrombosis, for example. Current anticoagulants reduce this tendancy to clot, and so reduce risk of thrombosis, but at the cost of increased propensity to bleed.
Ichorcumab, which is a synthetic analogue of a naturally-occuring antibody found in a patient presenting at Addenbrooke’s Hospital in Cambridge, is the first agent that offers the potential to prevent thrombosis without causing bleeding. Ichorcumab is currently in preclinical development, and we expect to perform the first clinical studies in 2015.